This paper aims to develop a tool for measuring the clients’ maturity in smart maintenance supply networks. The assessment tool is developed and validated for corporate facilities management organizations using case studies and expert consultation. Based on application of the assessment tool in five cases, conclusions are presented about the levels of maturity found and the strengths and limitations of the assessment tool itself. Also, implications for further research are proposed.
MULTIFILE
This book describes how policy workers and administrators of local councils and non-profit organisations can contribute to a social domain in which the people’s strengths are better utilized within the framework of the Social Support Act (Wmo). The book is built up around the three assignments a government sees itself faced with: - The transformation from less of a system world to more of a lifeworld. - The transformation from ‘steering’ in a less top-down to a more bottom-up way. - The transformation from less deductive to more inductive learning and development. In this book they describe how representatives of steering force can contribute to this transformation. In their conclusion, the authors state these representatives cannot ultimately fulfill the role of director in the transformation of the social domain geared to the strengths in the lifeworld. They can help to make the transformation less dependent on ‘higher powers’. The authors end their book with recommendations and suggestions for further research on the topic of WMO. This book is a translated version of “Outreachend besturen in tijden van transitie”, published by Movisie.
The global market for the industrial manufacturing of recombinant proteins (RPS) is steadily increasing and demand will keep rising in years to come. Currently, RPs are already an integral part of disease therapeutics, agriculture and the chemical industry and RP manufacturing methods rely heavily on host systems such as prokaryotes and, to a lesser extent, mammalian, yeast and plant cells. When comparing these host systems, all have their specific strengths and weaknesses and numerous challenges remain to improve protein manufacturing on an industrial scale. In this project, GLO Biotics proposes an innovative plant-based RP expression platform with the potential of significantly reducing costs and process requirements compared to the current state-of-the-art systems. Specifically, this novel concept is based on the use of coconut water as a natural, cell-free ‘protein production factory’. Coconut water in nuts aged 4-6 months is composed of free-floating cell nuclei devoid of cell walls, and it has been demonstrated these nuclei can express foreign proteins. Compared to existing platforms, the relative ease of delivering foreign protein-coding genes into this system, as well as the ease of recovery of the produced protein, potentially offers an innovative platform with great commercial attractiveness. In summary, the aim of this project is to provide a proof-of-concept for coconut water as a novel and competitive RP production platform by demonstrating the production and recovery of several commercially available RPs. To this end, GLO Biotics intends to collaborate with Zuyd University of Applied Sciences (Zuyd) and the Aachen Maastricht Institute for Biobased Materials (AMIBM) in demonstrating the potential of the ‘GLO-Conuts’ expression system. As a consortium, Zuyd and GLO Biotics will utilize their shared experience in molecular engineering and DNA vector technology and AMIBM will bring their expertise in plant-based RP production and recovery.
The growing awareness of consumers of the increasing problem with livestock and meat production due to the high nitrogen emissions and the related impact on climate change drives consumption of plant based vegetarian alternatives. Similarly there is also an increasing demand for animal-free, eco-friendly alternative vegan leather. Consequently there has been significant interest in developing leather-like vegan materials from multiple plant sources, such as mango, pineapple and mushroom based materials. However, the commercialization and the growth of sustainable vegan leather production is hampered significantly by the difficulty of achieving the needed quality for the various consumer products as well as the high prices of the vegan alternatives. In the Growing Leather project two SMEs, BioscienZ and B4Plastics, will combine forces with Avans University of Applied Sciences to develop vegan leather from the mushroom based material called mycelium. BioScienZ is a biotech company with strong expertise and capacity to produce low-cost and consistent quality mycelium. B4Plastics is a material development company, with strengths in designing and distributing eco-plastic products. In this project Avans University will use several mycelium types (produced by BioscienZ), and with the guidance of B4Plastics, it will test various additives under many different conditions, to ultimately develop an environmentally friendly, vegan material that will have comparable material characteristics to animal leather and is competitive in price.
Biotherapeutic medicines such as peptides, recombinant proteins, and monoclonal antibodies have successfully entered the market for treating or providing protection against chronic and life-threatening diseases. The number of relevant commercial products is rapidly increasing. Due to degradation in the gastro-intestinal tract, protein-based drugs cannot be taken orally but need to be administered via alternative routes. The parenteral injection is still the most widely applied administration route but therapy compliance of injection-based pharmacotherapies is a concern. Long-acting injectable (LAI) sustained release dosage forms such as microparticles allow less frequent injection to maintain plasma levels within their therapeutic window. Spider Silk Protein and Poly Lactic-co-Glycolic Acid (PLGA) have been attractive candidates to fabricate devices for drug delivery applications. However, conventional microencapsulation processes to manufacture microparticles encounter drawbacks such as protein activity loss, unacceptable residual organic solvents, complex processing, and difficult scale-up. Supercritical fluids (SCF), such as supercritical carbon dioxide (scCO2), have been used to produce protein-loaded microparticles and is advantageous over conventional methods regarding adjustable fluid properties, mild operating conditions, interfacial tensionless, cheap, non-toxicity, easy downstream processing and environment-friendly. Supercritical microfluidics (SCMF) depict the idea to combine strengths of process scale reduction with unique properties of SCF. Concerning the development of long-acting microparticles for biological therapeutics, SCMF processing offers several benefits over conventionally larger-scale systems such as enhanced control on fluid flow and other critical processing parameters such as pressure and temperature, easy modulation of product properties (such as particle size, morphology, and composition), cheaper equipment build-up, and convenient parallelization for high-throughput production. The objective of this project is to develop a mild microfluidic scCO2 based process for the production of long-acting injectable protein-loaded microparticles with, for example, Spider Silk Protein or PLGA as the encapsulating materials, and to evaluate the techno-economic potential of such SCMF technology for practical & industrial production.
